CClinicalTrials.gg
Status unknownNCT01774916Updated Sep 1, 2014

Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations

An interventional study of blood samples in Cutaneous Arteriovenous Malformations, sponsored by Assistance Publique Hopitaux De Marseille. Status unknown at 1 site in France. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-01.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable and Interventional

The sponsor has not verified this record recently (last verified Aug 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
10 Years and older
Sex
All
01

Study summary

Cutaneous Arteriovenous malformations (AVM's) rare congenital high-flow vascular malformations in which arteries and veins are directly connected through a complex web of abnormal arteries and veins instead of a normal capillary network. Arterial feeders and enlarged draining veins directly connect through arteriovenous fistulas that create the "nidus". The natural history of AVMs is organized into a clinical staging system: during the first phase of quiescence, the arteriovenous malformation mimics a capillary malformation. After many years, the AVM may enlarge with loco-regional expansion and tissular destruction. At the ultimate stage, AVM may impact the heart function. They are considered non malignant but can expand and become a significant clinical risk when extensive. The management of these high flow AVM remains often problematic. Complete and large surgical excision of the nidus after hyperselective embolization is the only potential therapeutic solution but this, is often difficult if not impossible. There is no pathogenetic hypothesis for the development of these malformations. Histopathological examination (performed only on surgical resection specimen) is poor and does not provide sufficient evidence to assess the evolutivity or the severity of the MAV. Recent data hypothesize that these vascular malformations are associated with alterations of the vascular endothelium caused by genetic abnormalities involved in the control of angiogenesis and vascular homeostasis. The detection of these anomalies allows the search for cellular and genetic markers that might be useful to optimize the clinical classification, staging, predicting the evolution of these defects and some understanding of its pathophysiological mechanisms. To our knowledge, no studies to identify cellular markers / genetic and endothelial associated with the development of cutaneous AVMs have been published to date.

02

Conditions studied

  • Cutaneous Arteriovenous Malformations
03

In context

Hemangioma

141 studies on the registry are indexed under Hemangioma; 16 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 80 interventional studies indexed under Hemangioma.

Browse Hemangioma studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 686 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or feminine Subject
  • Subject of 10 and more years old,
  • Subject weighing more than 55 kg. patients:
  • Subject presenting a cutaneous artério-venous deformation there outside of any other deformation or known vascular tumor.
  • Subject presenting no other susceptible pathology to influence endothéliaux markers (Renal insufficiency, inflammatory pathology chronicles, infections, pathologies cardiovascular, diabetes, evolutionary tumoral pathology).

volunteers:

  • Unhurt Subject of deformation or vascular tumor.
  • Subject presenting no other susceptible pathology to influence endothéliaux markers(scorers) (Renal insufficiency, inflammatory pathology chronicles, infections, pathologies cardiovascular).

Exclusion criteria

Exclusion Criteria:

  • Subject of less than 10 years old
  • Subject weighing less than 55 kg
  • Subject presenting another type(chap) of vascular vascular deformation or tumor
05

Study design

Phase
Not applicable
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    patients

    Genetic: blood samples

  • Other
    volunter

    Genetic: blood samples

Interventions

  • Geneticblood samples
06

What researchers measure

Primary outcomes

  1. The exploration of the microparticles, endothelial cells and progenitor cells

    Time frame: 36 months

Secondary outcomes

  1. investigate the relationship between endothelial markers and genetic and clinical characteristics of the disease

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Assistance Publique Hopitaux de Marseille
    Marseille, 13006, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01774916
Lead sponsor
Assistance Publique Hopitaux De Marseille
Responsible party
Sponsor
First posted
Jan 24, 2013
Start date
Jan 2013
Primary completion
Jan 2016 (estimated)
Completion
Jul 2016 (estimated)
Last update
Sep 1, 2014

Study contacts

Nathalie Degardin
Contact
nathalie.degardin@ap-hm.fr
michele DAMON
study director · Assistance Publique Hopitaux De Marseille

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion